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Abstract Diabetes is associated with a greatly increased
risk of cardiovascular disease (CVD), which cannot be
explained only by known risk factors, such as smoking,
hypertension, and atherogenic dyslipidemia, so other fac-
tors, such as advanced glycation end-products (AGEs) and
oxidative stress, may be involved. In this frame, hyper-
glycemia and an increased oxidative stress (AGE forma-
tion, increased polyol and hexosamine pathway flux, and
protein kinase C activation) lead to tissue damage, thus
contributing to the onset of cardiovascular complications.
Several studies have identified in various cell systems, such
as monocytes/macrophages and endothelial cells, specific
cellular receptors (RAGE) that bind AGE proteins. The
binding of AGEs on RAGE induces the production of
cytokines and intracellular oxidative stress, thus leading to
vascular damage. Soluble RAGE levels have been identi-
fied as hypothetical markers of CVD, but, in this regard,
there are sparse and conflicting data in the literature. The
purpose of this review was to examine all the available
information on this issue with a view to clarifying or at
least highlighting the points that are still weak, especially
from the point of clinical view.
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Introduction
Diabetes is associated with a two- to fourfold increase in
the risk of coronary, cerebral, and peripheral artery disease.
Seventy to eighty percent of people with diabetes die of
atherosclerosis-related disease [1, 2]. Atherosclerosis
develops much earlier in life and progresses at a faster rate,
in diabetic patients than in individuals without diabetes.
Despite the high prevalence of risk factors, no more than
25 % of the excess cardiovascular risk in diabetes can be
attributed to known risk factors, for example, smoking,
hypertension, and atherogenic dyslipidemia [3], so other
factors, such as advanced glycation end-products (AGEs)
[4–6], oxidative stress [7], and thrombophilic state [8], may
be involved. In this sense, hyperglycemia is an important
contributor to the onset of cardiovascular complications.
Among the biochemical alterations characteristic of
hyperglycemia, the factors involved in causing athero-
sclerotic disease include the formation of AGEs, an
increased polyol pathway flux and hexosamine pathway
flux, and protein kinase C activation [9–12]. All of these
molecular mechanisms reflect a single hyperglycemia-
induced process of superoxide overproduction by the
mitochondrial electron transport chain. Hyperglycemia and
an increased oxidative stress [13] thus lead to tissue dam-
age via common pathways.
While the role of AGEs and their capacity to predict
cardiovascular disease (CVD) in type 2 diabetic patients is
now recognized, the published literature on other hypo-
thetical markers, such as sRAGE and esRAGE, is sparse
and conflicting. The reason why the picture is still not clear
probably lies in the fact that soluble RAGE levels in
humans depend on two mechanisms, that is, alternative
splicing of the RAGE gene (esRAGE) and cleavage of the
full-length protein (sRAGE).
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The primary purpose of this review was to examine all
the available information on this issue with a view to
clarifying or at least highlighting the points that are still
weak and need further investigation and clinical insight to
arrive at a synthesis and interpretation of the controversial
data in the literature.
AGE formation
The non-enzymatic glycation of proteins, or Maillard
reaction, is a process that links chronic hyperglycemia to a
series of physiopathological changes considered important
in the development of the chronic complications of dia-
betes [14]. The Maillard reaction is divided into three main
stages: early, intermediate, and late.
In the ‘‘early stage,’’ glucose (or other reducing sugars,
such as fructose, the pentoses, galactose, mannose, ascor-
bate, and xylulose) reacts with a free amino group of
several molecules, including proteins, nucleic acids, and
lipids, to form an unstable aldimine compound, the Schiff
base. Through rearrangement, this base gives rise to a
stable ketoamine, the Amadori product. Since this reaction
does not require the participation of enzymes, the variables
regulating it in vivo are the glucose and protein concen-
trations, the protein’s half-life and its reactivity in terms of
free amino groups, and cell permeability to glucose. Under
in vivo conditions, the Amadori product reaches an equi-
librium after approximately 15–20 days, and, through
irreversible links, it accumulates on both short-lived and
long-lived proteins.
In the ‘‘intermediate stage,’’ involving oxidation and
dehydration reactions, the Amadori product degrades into a
variety of carbonyl compounds (glyoxal, methylglyoxal,
deoxyglucosones) much more reactive than the sugars from
which they derive; these compounds act as propagators,
again reacting with the free amino groups of proteins. In
particular, methylglyoxal is a highly reactive alpha-oxal-
dehyde formed both from reactions that depend on the
glucose levels (non-enzymatic glycation, the polyol path-
way) and from intermediate products of glycolysis, ketone
body metabolism, and threonine catabolism. The marked
reactivity and high plasma concentrations of methylglyoxal
indicate that this is one of the most important compounds
in vivo [15].
In the ‘‘late stage,’’ these propagators react again with
free amino groups, and through oxidation, dehydration and
cyclization reactions, they form yellow–brown, often fluo-
rescent, insoluble, irreversible compounds (usually called
AGEs), which accumulate on long-lived proteins and cause
damage. Although the chemical nature of these compounds
has yet to be clearly defined, recent investigations indi-
cate that they include post-Amadori products deriving
from oxidation and further structural rearrangements, so
compounds that are neither cross-linked nor fluorescent
have been assumed to belong to the AGE group. It should be
emphasized here that oxidation processes are important in
the formation of many AGEs [16]. There are two mecha-
nisms behind these processes, both catalyzed by metals such
as copper and iron: the first involves the auto-oxidation of
free sugar in the presence of oxygen and free metals,
leading to more reactive dicarbonyl compounds that react
with proteins to form highly reactive ketoamines; the sec-
ond mechanism involves protein-bound products of the
Amadori pattern that are oxidized in the presence of oxygen
and free metals, giving rise to highly reactive protein-
enediols and protein-dicarbonyls, which can generate
AGEs.
Markers of glycoxidation
The change in color seen in glycated products in early
studies prompted the use of spectroscopic methods (based
on absorbance and fluorescence measurements) for their
analysis, but these methods lacked specificity [14]. The
more specific methods, based on HPLC, radioimmunoassay
(RIA) and enzyme-linked immunosorbent assay (ELISA),
subsequently used to study glycoxidation markers [17],
have their limitations too, however, since they are unable to
identify glycoxidation products structurally and they
sometimes generate misleading results, as in the case of the
first glycoxidation product identified—the FFI compound
[18].
Mass spectrometry (a technique with a high sensitivity
and specificity) has been applied more recently to studying
glycoxidation in diabetic disease. Matrix-assisted laser
desorption mass spectrometry (MALDI/MS) has identified
a number of compounds after the in vitro incubation of
protein with glucose [19, 20]; these compounds need to be
tested under in vivo conditions, however, to confirm their
clinical importance. MALDI/MS has also been applied
successfully to the study of glycation and oxidation
kinetics of such well-known proteins as albumin and glo-
bin, providing us with useful information about what
happens in vivo [21]. A method based on LC/MS/MS was
also used for the quantitative measurement of 16 biomark-
ers of protein glycation, oxidation, and nitration damage
[22]. This investigation proved that hydroimidazolones are
the most important glycoxidation biomarkers. In type 1
diabetic patients, the concentrations of protein residues
modified by glycation show a twofold increase in hemo-
globin A1 by comparison with healthy subjects. The plasma
concentration of free adducts increases tenfold in the same
patients, but no studies correlating these markers with
chronic diabetic complications have been performed to
date.
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Among the AGEs, carboxymethyl-lysine (CML) has a
well-characterized structure and is considered a glycoxi-
dation product because a pro-oxidizing condition is needed
for its formation; it is recognized by RAGE and capable of
directly activating the AGE-RAGE-NF-kB axis [23]. It has
been demonstrated that the CML formed by protein-bound
glycated lysine oxidation is a major AGE in vascular
lesions and that its level is associated with macrovascular
complications in diabetic patients [24].
Pentosidine is a structurally characterized marker of
cross-linking induced by glycoxidation; it is associated
with early atherosclerosis in type 2 diabetic patients
(increased carotid intima-media wall thickness [25] and
arterial stiffening [26]), and also with advanced athero-
sclerosis, in term of peripheral artery disease (PAD) [27].
The role of AGEs in diabetic macroangiopathy
AGEs are formed by the glycation or glycoxidation of
proteins, lipids, and nucleic acid and have been linked to
the accelerated atherosclerosis seen in diabetic patients.
There are essentially three main mechanisms behind the
tissue damage caused by AGEs, that is, intracellular gly-
cation, cross-link formation, and interaction with specific
cellular receptors [28].
Intracellular glycation
The first mechanism of AGE-induced damage is a conse-
quence of hyperglycemia-induced intracellular accumula-
tion (demonstrated in macrophages and in endothelial and
smooth muscle cells) and the resulting alteration of cyto-
plasmic and nuclear structures, including proteins involved
in regulating gene transcription [29]. The accumulating
AGEs spread out of the cell, inducing non-receptor-
dependent changes in the extracellular matrix molecules
[30] and modifying circulating proteins, which then bind to
AGE cell receptors; this binding prompts the production of
inflammatory cytokines, which in turn cause vascular
injury [31].
Cross-link formation
This involves mechanisms classifiable as non-receptor
dependent, of which one of the most important is the for-
mation of stable abnormal cross-links on collagen, as
demonstrated by in vitro incubation with glucose and also
in vivo in the collagen of diabetic patients. The numerous
chemical and physical changes to collagen caused by gly-
coxidation can explain some of the structural tissue mod-
ifications typical of the chronic complications of diabetes,
such as vascular and arterial stiffening, and basement
membrane thickening. The non-enzymatic glycation of
collagen can also inhibit the release of endothelium-
derived nitric oxide, with consequent vasoconstriction,
reduced plasma flow, and tissue ischemia. Lastly, AGE
compounds in collagen may trap multiple macromolecules
such as lipoproteins, immunoglobulin, fibrin, and albumin.
Immunoglobulins bound to collagen retain their ability to
form antigen–antibody complexes, which may become
deposited on the vessels. In addition, trapped immuno-
globulin could trigger complement activation, resulting in
tissue damage, and glycated LDL (AGE-LDL) also binds
covalently to glycated collagen, thus contributing to vessel
occlusion. Other mechanisms involved in the formation of
atherosclerotic plaques may cause vessel occlusion too. For
a start, AGEs (and particularly CML-LDL) [5, 32] are not
identified by their receptor, they are preferentially recog-
nized by scavenger receptors on monocytes/macrophages,
and this enhances their uptake with a consequent stimula-
tion of ester-cholesterol synthesis and ‘‘foam cell’’ forma-
tion. Second, glycated LDLs are capable of stimulating
thromboxane b2 release and inducing platelet aggregation.
Third, glycated lipoprotein may generate free radicals,
prompting more vessel oxidative damage. It has been
suggested that LDL glycation may increase susceptibility
to oxidation [33] and thus contribute, together with small/
oxLDL, to accelerating atherosclerotic processes. Finally,
because of their altered structure, AGE-LDLs are immu-
nogens and can therefore stimulate the production of
antibodies, as well as oxLDL; the resulting immune com-
plexes may deposit on vessel walls and stimulate ‘‘foam
cell’’ formation (in the case of AGE-LDLs) or IgG oxLDL
antibodies within atherosclerotic lesions, which are mark-
ers of an advanced stage of the atherosclerotic process [34].
Interaction with specific cellular receptors
Several studies have identified specific cellular receptors
(RAGEs) that bind AGE proteins in a saturable manner.
The RAGE was identified as a new member of the Ig
superfamily of cell surface molecules, codified from a gene
on chromosome 6. This receptor was subsequently identi-
fied in various cell systems, such as, monocytes/macro-
phages, T lymphocytes, fibroblasts, smooth muscle cells,
endothelial cells, neurons, red cells, and mesangial cells.
The binding of AGEs on RAGEs of T lymphocytes stim-
ulates the production of gamma-interferon, with conse-
quent tissue damage; the binding of AGEs to monocytes/
macrophages (Fig. 1) induces the production of cytokines
(interleukin 1B, TNF-alpha, IGF-1, PDGF) and growth
factors, with a consequent increase in the synthesis of type
IV collagen, a greater proliferation of vessel smooth
muscle cells, and a stimulation of macrophage chemotaxis.
Through a mechanism of oxidative stress, AGE-RAGE
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binding on endothelial cells induces the transcription factor
NF-kB, which in turn increases the expression of the vas-
cular cellular adhesion molecule (VCAM-1) (Fig. 1). The
resulting VCAM-1 overexpression increases the adhesivity
of monocytes to endothelial cells, and vascular perme-
ability, speeding up the trans-endothelial passage of AGE-
modified proteins (and AGE-LDL in particular). Other
changes seen as a consequence of this AGE-RAGE inter-
action are an increased pro-coagulant response to TNF-
alpha, a reduced thrombomodulin expression, and higher
endothelin-1 levels. In diabetes, the binding of AGE to
RAGE reduces tissue protein degradation and increases
growth factor production, with a consequent increase in the
synthesis of extracellular matrix and impairment of tissue
remodeling mechanisms. In addition to oxidative stress, the
absence of an appropriate compensatory response from the
endogenous antioxidant network has also been implicated
in systemic endothelial dysfunction [35, 36], of which
microalbuminuria is considered a marker [37]. In this
context, we found that microalbuminuria in type 2 diabetic
patients might be promoted by an insufficient counter-
regulation of the antioxidant system in the event of
increased glycoxidation/glycation [38].
In short, AGEs contribute to endothelial damage via
several mechanisms, including intracellular protein modi-
fications, the formation of cross-links in the extracellular
matrix, and interaction with the receptor for AGEs, that is,
RAGE [39]. This receptor is a multiligand member of the
Ig superfamily of cell surface molecules [40] that engages
AGEs and leads to cellular signaling, including nuclear
factor kB (NF-kB) activation, increased cytokine and
adhesion molecule expression, the induction of oxidative
stress [41], and an increase in cytosolic reactive oxygen
species [42]. RAGEs may therefore have a part to play in
the development of vascular disease in diabetic patients
[43]. It is worth noting at this point that, in addition to the
RAGEs, a number of RAGE ligands have been identified in
diabetic patients, including members of the S100 calgran-
ulin family and high-mobility group box 1 (HMGB1).
These ligands’ interaction with RAGE can trigger a sub-
sequent interaction with an innate immune system signal-
ing molecule, the toll-like receptor 4 (TLR-4) [44].
The soluble RAGE isoform (sRAGE) expresses the
cellular concentration of RAGE and reflects the total pool
of soluble RAGE in plasma, which includes several vari-
ants. The exact role of sRAGE in plasma is unknown, but it
may differ between different variants. Endogenous soluble
RAGE (esRAGE) is a circulating truncated variant of the
RAGE isoform that can neutralize AGE-mediated damage
by competing with cell surface RAGE for ligand binding.
EsRAGE is generated by the alternative splicing of the pre-
mRNA RAGE transcript, and it is characterized by a spe-
cific C-terminal 16-amino-acid sequence [45]. EsRAGE
accounts for most of the total soluble RAGE isoform
(sRAGE) [46] detectable in the plasma using antibodies
against full-length sRAGE (the three extracellular immu-
noglobulin domains) or antibodies specific for esRAGE.
Antibodies against sRAGE recognize both sRAGE and
esRAGE, but antibodies selectively reacting to esRAGE
will not recognize other sRAGE-like molecules [47].
Plasma levels of esRAGE reflect receptor expression levels
more directly than those of sRAGE [48].
Metabolic memory
The results of the EDIC study [49, 50] on type 1 diabetic
patients and those coming from the follow-up after the
UKPDS study [51] on type 2 diabetic patients showed that
patients who achieve a good metabolic control with
intensive treatment when their diabetes is first diagnosed
continue to benefit from a lower risk of chronic diabetic
complications even if their glycemic control becomes
worse. This is due to a phenomenon called ‘‘metabolic
memory’’ or the ‘‘legacy effect’’ and can be explained by
persistent epigenetic changes prompted by the increase in
mitochondrial superoxide levels induced by hyperglyce-
mia. Briefly put, hyperglycemia raises the mitochondrial
production of ROS, and this activates the NF-kB subunit
Fig. 1 Cellular binding of advanced glycation end-products induces
atherosclerosis. The mechanisms by which advanced glycation end-
product (AGE) binding to specific receptors (RAGE) on macrophages
and endothelial cells may cause atherosclerotic changes in diabetic
blood vessels. On both cells, AGE-RAGE binding stimulates
production of tumor necrosis factor (TNF)-a, interleukin-1 (IL-1),
and insulin-like growth factor-1 (IGF-1) at levels that induce a pro-
inflammatory process. On endothelial cells, AGE-RAGE binding
induces increased expression of leukocyte-binding vascular adhesion
molecule-1 (VCAM-1), increased intracellular oxidative stress and
consequently reduced NO, and increased production of endothelin-1
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p65 in the proximal promoter with a consequent increase in
the expression of p65-dependent proinflammatory genes.
Activation of the proinflammatory genes of human aorta
endothelial cells can induce macroangiopathy [44]. In
parallel, the increased formation of stable AGE cross-links
on collagen vessels can also contribute to the onset of
micro- and macroangiopathy: in this frame, it has been
suggested that hyperglycemia-induced functional and
structural alterations in the microcirculation interact in the
vascular continuum with larger arteries, that is, microvas-
cular changes within the vessel wall can promote athero-
sclerosis in the larger arteries. Microvascular changes
occurring in the first stage of diabetic disease could be
reversible if the patient’s hyperglycemia is corrected
promptly; if it is not, the resulting macrovascular changes
are irreversible [52].
AGEs and the AGE-RAGE axis: clinical implications
in type 2 diabetes
AGEs play an important part in the development of car-
diovascular complications in patients with type 2 diabetes.
From the first observations of high AGE levels in athero-
sclerotic coronary plaque in selected type 2 diabetic
patients [53] to Kiuki et al.’s demonstration that serum
AGE concentrations increase consistently with the severity
of coronary atherosclerosis in type 2 diabetic patients with
obstructive coronary artery disease [54], the hypothesis that
AGE concentrations may be a risk marker in type 2 dia-
betic patients with coronary atherosclerosis has taken shape
and has been put to the test. A few years ago, the role of
CML (one of the most often measured AGEs) was inves-
tigated in patients with ischemic heart disease (IHD) with
and without type 2 diabetes [55]: patients with IHD and
type 2 diabetes had significantly higher CML levels than
diabetic patients without IHD. The authors concluded that
the higher CML levels reflected the enhanced oxidative
stress due to higher blood glucose levels in diabetic IHD
patients. Data obtained in senile diabetic patients with and
without cardiovascular complications appeared soon
afterward [56] in a study in which serum AGEs were found
significantly higher in senile diabetic patients with car-
diovascular complications. The two studies suggested
using serum CML or AGEs, respectively, as a useful
independent biomarker of cardiovascular complications
due to type 2 diabetes mellitus. There were no prospective
data available at the time to confirm this recommended ion,
however. A study confirming CML as a valid marker
appeared 3 years ago, though it did not concern diabetic
patients [57]. After a 6-year follow-up, Semba et al. found
that plasma CML was an independent predictor of CVD-
related and all-cause mortality in a population of elderly
adults (without diabetes mellitus), without providing data
on specific adverse cardiovascular outcomes, such as
myocardial infarction or stroke. Table 1 lists the latest
studies that move in this same direction, further supporting
the association between glycoxidation and cardiovascular
events or complications in type 2 diabetes. The results of
these studies show a strong correlation between glycoxi-
dation markers and the onset of complications, in terms of
cardiovascular events or vascular damage in type 2
diabetes.
Measuring serum levels of AGEs might pinpoint indi-
viduals at higher risk of cardiovascular complications.
Increased serum levels of AGEs have been found to predict
both cardiovascular and coronary mortality in women with
type 2 diabetes, even during a follow-up spanning 18 years
[58]. Very recently, the same results were seen by Nin et al.
[59] in type 1 diabetic patients after a follow-up lasting
12 years. In type 2 diabetes, glycoxidation might contribute
to the development of atherosclerosis not only in coronary
arteries but also in the below-the-knee peripheral artery
tree, as suggested by Lapolla et al. [27]. In particular,
pentosidine levels were found much higher in type 2 dia-
betic patients with PAD than in cases without this condition,
and pentosidine may be a predictor of PAD in type 2 dia-
betes. Certainly, the current data warrant an appropriately
designed longitudinal study to confirm this hypothesis.
It is worth noting here that serum AGE levels do not
necessarily correlate with fasting plasma glucose or recent
glycated HbA1c levels, as Kilhovd et al. and Lapolla et al.
have both observed; this is probably because the rate of
AGE turnover is unrelated to glucose levels, whereas long-
term poor glycemic control correlates with AGE produc-
tion [54]. Even a long period of good metabolic control is
unable to normalize the levels of glycoxidation products,
such as pentosidine, showing that hyperglycemia causes a
persistent oxidative stress that is able—per se and regard-
less of glucose concentrations—to induce and potentiate
AGE formation in diabetic patients [60].
In hemodialysis patients too [61], plasma levels of
AGEs, such as CML and pentosidine, have been associated
with the levels of cardiac troponin T, a biomarker of
myocardial damage used in the diagnosis of acute myo-
cardial infarction and acute coronary syndrome. So, AGEs
may be involved in the onset of myocardial damage in IHD
patients too, including those with type 2 diabetes; AGEs
accumulate in renal failure as well, due to their decreased
excretion and increased generation caused by oxidative and
carbonyl stress in uremia.
Four years ago, Basta [41] focused on the RAGE-ligand
axis as an important player in modulating several steps of
atherogenesis. AGEs induced oxidative stress through
interaction with RAGEs. This has drawn a good deal
of attention to the interaction between glycoxidation
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parameters and serum RAGE, which prompts an increased
inflammatory reaction, supporting the pathogenic role of
RAGE in the development and progression of atheroscle-
rosis. Yan et al. [62] suggested that this interaction, toge-
ther with the inflammatory cascade that follows, leads to
coronary heart disease (CHD) in which the protective
esRAGE levels are attenuated, as in type 2 diabetic
patients. This picture was confirmed by Lu et al. [63] in a
cross-sectional study and by Peng et al. [64] over a one-
year period, who demonstrated an association between
decreased esRAGE levels and coronary artery disease
(CAD) severity or progression in patients with type 2
diabetes, respectively. Lower esRAGE levels, combined
with an intensified inflammatory process, were associated
with an accelerated atherosclerotic process. Here again, a
thorough characterization of the protective function of
esRAGE against plaque progression in T2DM patients is
needed, based on serial observations over a long-term
follow-up. More evidence of the association between
esRAGE and diabetic cardiovascular complications in
patients with T2DM has now become available. In parti-
cular, we ourselves [65] found significantly lower plasma
esRAGE levels in diabetic patients with plaque than in
those without plaque, along with higher levels of AGEs.
We also made the original finding that esRAGE levels only
correlated directly with glycoxidation parameters in
patients with no plaque, suggesting that there are two
different phenotypes of type 2 diabetic patients with a
different susceptibility to glycoxidation. In patients without
macrovascular complications, esRAGEs seem to have a
vessel-protecting role and the capacity to neutralize
glycoxidation.
An interesting recent study [66] found higher circulating
sRAGE levels in patients with acute coronary syndrome
and positive troponin I than in cases with normal troponin
I. The study sample also included some type 2 diabetic
patients, but their number was not stated. This was an
observational study so no final conclusions can be drawn
from it, but the authors hypothesized that acute myocardial
injury, by inducing inflammatory reactions, could be a
prominent stimulus for the release of sRAGE. Similar
results in a prospective study on type 1 diabetic patients
[67] reinforce the idea of a strong association between
higher plasma sRAGE levels (as a reflection of RAGE
expression) and fatal or non-fatal CVD-related events. In
another recent study [68], the possible role of sRAGE and
esRAGE in type 2 diabetic patients was extended to a
subgroup analysis on patients with acute myocardial
infarction (AMI). Plasma levels of sRAGE were higher in
response to circulating AGEs in the type 2 diabetic patients
with AMI than in the diabetic controls, and on multiple
logistic regression analysis, they were independently
associated with AMI. The plasma levels of esRAGE were
similar in the two groups, however. The studies by Basta
[66] and Park [68] help to clarify the role of sRAGE levels
in type 2 diabetic patients, in whom they are positively and
independently associated with the presence of CAD. In
type 2 diabetes, sRAGEs lose their protective effect and
their proinflammatory property prevails because of the
specific state induced by the disease.
Table 1 The latest studies that support the association between glyco-oxidation and cardiovascular events or complications in type 2 diabetic
patients
Author (year) n Type of study AGEs esRAGE sRAGE Complication
Kilhovd (2007) 386 Longitudinal : – – Mortality (total, CVD, IHD) in women
Lapolla (2007) 33 Cross-sectional : – – PAD
Yan (2008) 151 Cross-sectional – ;* : CAD
Lu (2009) 357 Cross-sectional – ; – CAD
Peng (2009) 42 Longitudinal – ! – CAD progression
Basta (2011) 58 Cross-sectional – – : IHD
Park (2011) 27 Cross-sectional – $ : AMI
Colhoun (2011) 167 Longitudinal – : : IHD
Chen (2011) 58 Cross-sectional : ; – PAD
Yang (2012) 41 Cross-sectional – $; $; Carotid plaque inflammation
AMI acute myocardial infarction, CAD coronary artery disease, CVD cardiovascular disease, IHD ischemic heart disease, PAD peripheral artery
disease, esRAGE endogenous soluble receptor for AGE, sRAGE soluble receptor for AGE
* only esRAGE independently associated with CAD
! from baseline in diabetic patients with plaque progression
$ similar between patients with and without AMI
$; tenderness to be lower (P\0.07) vs healthy controls
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Two further studies have recently showed more light on
the role of sRAGEs and esRAGEs in cardiovascular
complications. A prospective study conducted by Colhoun
et al. [69] showed that higher sRAGE and esRAGE levels
are associated with future CHD, but not stroke, in type 2
diabetes. Another interesting finding that was not empha-
sized enough was that sRAGEs and esRAGEs seem to have
no significant association with classical CVD risk factors
such as smoking, lipids, blood pressure, or duration of
diabetes, and no more than 6 and 10 % of the variance in
sRAGE and esRAGE levels, respectively, was explained
by BMI, ethnicity, HbA1c, or eGFR, which goes to show
their independent role in predicting CHD events. In a cross-
sectional study [70] examining a situation of frank car-
diovascular damage, lower serum esRAGE levels and
higher serum AGE levels were found associated with
dyslipidemia and atherosclerosis in patients with type 2
diabetes. The authors attributed the decrease in serum
esRAGE to three possible mechanisms: (1) chronic
hyperglycemia directly inhibiting the synthesis and secre-
tion of esRAGEs, (2) the accumulated AGEs binding to
esRAGEs and leading to their greater clearance, and
(3) inflammation interfering with esRAGE synthesis.
Park et al. [68] added a relevant observation that points
in the direction of a close relationship between sRAGE and
inflammation: they suggested that interactions between
AGEs and their receptor RAGEs may be anti- or pro-
inflammatory depending on the inflammatory milieu. In
AMI, this mechanism ultimately results in macrophage
infiltration at the site of atherosclerotic plaque and a worse
inflammatory state, which destabilizes the fibrous cap tis-
sue, enhancing the risk of rupture; this would be consistent
with the finding of a RAGE overexpression associated with
enhanced inflammatory reactions in the vulnerable region
of the plaque in carotid endoarterectomy specimens [71].
A more severe carotid plaque inflammation in type 2 dia-
betic patients than in healthy controls has already been
observed [72] using a specific technique to detect inflam-
matory carotid atherosclerotic plaque. Circulating sRAGE
and esRAGE concentrations tended to be lower in the
diabetic group, albeit without reaching statistical signifi-
cance. A significant negative independent association
between vascular inflammation and sRAGE levels was
observed, but not between sRAGE and intima-media
thickness (IMT), in all the subjects evaluated (both diabetic
patients and healthy controls), making it difficult to
establish the real association between this picture and
diabetes. Considering that IMT provided no information on
plaque composition or inflammatory state, the lack of
association with sRAGE is not surprising.
A recent study [73] providing new information on the
correlation between glycoxidation factors like AGEs and
pentosidine and diabetic cardiomyopathy supports the
hypothesis that AGEs can induce subclinical diastolic
dysfunction in type 2 diabetic patients. More importantly, it
demonstrates that a decline in antioxidant defenses corre-
lates closely with a worsening diastolic dysfunction. In this
context, the interaction between glycoxidation and anti-
oxidant status seems to play an important part in T2DM-
related endothelial dysfunction, confirming previous results
[38] (Fig. 2) .
Conclusion
Taken together, all the above-mentioned studies have
shown that glycoxidation has a significant role as a medi-
ator of T2DM-related cardiovascular complications, but it
seems from the available evidence and from this review,
that this role is only starting to be delineated. Both
sRAGEs and esRAGEs have been suggested as biomarkers
of CVD, but the studies conducted to date have formulated
different hypotheses, and there is a paucity of prospective
data. In particular, the crucial contribution of sRAGE to
accelerated atherosclerosis through the activation of
cellular inflammatory and proliferative processes needs
to be clarified in further longitudinal studies with a view to
confirming their capacity to predict the onset of cardio-
vascular complications, particularly in the carotid arteries.
Although we are still far from a thorough understanding of
serum level sRAGE behavior, we have to start thinking of
RAGE in a dynamic role, switching from higher levels in
the early stages of inflammation and atherosclerosis to a
gradual mild decline in the intermediate stage, before
increasing again in the acute phase of tissue damage and
consequent inflammation. This dynamism may help to
explain the different results obtained depending on the
Fig. 2 Behaviour of serum level of AGEs, sRAGE, and esRAGE in
atherosclerotic process occurring in type 2 diabetes: a working
hypothesis. AGE, soluble RAGE in a dynamic role, switching from
higher levels in the early stages of inflammation and atherosclerosis to
a gradual mild decline in the advanced stage of atherosclerosis, before
increasing again in the acute phase of tissue damage(clinical events)
and consequent inflammation
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inflammatory conditions and also on the area or intensity
of the damage. It is important here to bear in mind the
previously mentioned hypothesis that the type 2 patient
phenotype could be particularly important, since the
expression of alternative RAGE splicing could be geneti-
cally determined, featuring a different susceptibility to
glycoxidation.
Finding that type 2 diabetic patients have markedly
decreased esRAGE levels and increased levels of its ligand
(AGE), resulting in a significantly higher atherosclerotic
burden, highlights the importance of esRAGE in the pro-
atherogenic mechanisms at work in type 2 diabetes. EsRAGE
might be an endogenous factor that protects against athero-
sclerosis and endothelial dysfunction mediated by oxidative
stress, and part of the cell’s anti-oxidative defenses against
vascular damage. The idea that their measurement should be
recommended in type 2 diabetic patients needs to be tested in
prospective studies on large samples in order to fully eluci-
date the relationship between esRAGEs and cardiovascular
complications in type 2 diabetic patients.
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